The European Molecular Biology Laboratory (EMBL) and Enamine, have collaborated to develop novel small molecules which works against anti-cancer targets. As per the terms of this collaboration, Enamine is providing medicinal chemistry, library synthesis, and biological services to EMBL for their cause and together they expect to focus on creating new cancer therapeutics and novel modes of action. The collaboration comprises the deployment of medicinal chemists who are Full Time Equivalent (FTE), at Enamine.
Millions of Compounds Needed to Up Chemical Diversity at Screening Decks
For many years, the EMBL has been working with Enamine to improve the chemical space of their screening library, stated the Head of Chemical Biology Core Facility at EMBL, Joe Lewis. With the realization that above 2 mn collection of compounds can provide quality compounds, there is a need for increasing the chemical diversity of their screening deck. Thus, Enamine was chosen to outsource for their medicinal chemistry discovery program, as the company can help in the field of drug development and chemical biology.
Integration of Chemistry and Biology Service Portfolio
As per David Will, the Head of Medicinal Chemistry at EMBL, the collaboration with Enamine will help their project’s goal of identifying the targets from phenotypic screens, and then synthesizing and triaging patentable preclinical compounds that are new. The access to the world’s largest collection of building blocks at Enamine will go a long way in developing a preclinical compound. The integration of chemistry and biology service portfolio is apt for this kind of research.
“Our collaboration with EMBL illustrates our established engagement with non-profit academic research institutions and disease foundations in their search for strong and committed partners in the most challenging discovery research projects. We look forward to our continued successful work with EMBL”, concluded Michael Bossert, Head Strategic Alliances at Enamine.
RepliCel Life Sciences Inc., a company which specializes in developing cell therapies for orthopedic and aesthetic conditions, received a U.S. patent on April 25, 2017 for its new, multi-needle dermal injection devices. These devices fit as a solution to soaring need for dermal injection technologies capable of bringing high levels of control and precision to any elements injected into the skin.
The patent received from the U.S. Patent and Trademark Office (USPTO) covers technologies designed to allow both repeatable consistency and unparalleled control of product deposition and needle action. The patent also includes the component developed to numb the skin before using injection, with the intention to reduce, if not eliminate, the requirement for local anesthetic prior to aesthetic injection processes.
RepliCel Inches Closer to Launch of RCI-02 with Patent Issued
The first device being designed under the umbrella of this patent is RCI-02, which will be useful in injecting soft tissue fillers, including hyaluronic acid (“HA”). The device is also being designed for injecting RCS-01 skin rejuvenation and RCH-01 hair restoration products. It is expected to be optimized for other injectable such as biologics, drugs, fat grafts, and biologics.
With this patent, the company’s property portfolio has reached a new milestone. The portfolio already included two European patents for RCI-02. Company officials believe that this multi-needle device will be able to deliver unprecedented reproducibility, reliability, and programmability of 3D skin injections, making desired outcomes a much easier thing to attain for both clinicians and less-experienced injection specialists. The prototypes are estimated to get ready by the third quarter of 2017 for initial usability and functional testing by engineers and end users.
Anyone operating in the medical equipment and technology sector should have an insight into this recently discovered ‘mother of all acquisitions.’ C.R. Bard, a medical device behemoth, has been sold to fellow giant company Becton, Dickinson and Company. Bard has agreed to function under the leadership of Becton Dickinson in a titanic deal of US$24.0 bn or thereabouts.
Companies that supply to hospitals and healthcare centers have attracted eyeballs after the mega deal. The eye-watering acquisition deal kicked Bard’s shares up to almost 20.0% on Monday. Bard will receive an approximately over 25.0% than its share close price of April 21, 2017. This means that Becton Dickinson will bless Bard with a handsome US$317.0 per share, which could be in cash and shares.
Medical Supply and Healthcare Sectors on Merger and Acquisition Spree
Pricing pressure and the need to expand product portfolio are the top reasons that the medical devices sector is witnessing a series of mergers and acquisitions. However, Bard has a different, rather positive, perspective this its acquisition by Becton Dickinson. It will look to leverage the superintendence of Becton Dickinson in infection prevention and medication management to offer worthwhile advantages to patients and customers.
A couple of years back, CareFusion Corp was acquired by Becton Dickinson for exactly half the price of the Becton Dickinson-Bard deal, whereas Abbott Laboratories had acquired St. Jude Medical, Inc. for a billion more than the mega deal price in January 2017.
The scenario of mergers and acquisitions is not merely followed by medical equipment companies, hospitals are also part of the strategy as they share office with larger centralized operations and health systems.
Millions of Americans are prey to the newest bad habit that seems to be worse than smoking. Long hours of sitting and sedentary lifestyles have led to a wide range of health issues in the U.S. Desk jobs, recreational activities such as watching TV, playing video games, and long hours of sitting is proving to be a fatal pastime. Thankfully, smoking is down to 17% at the moment from 42% in 1965 due to laws and regulations preventing smokers from lighting up at restaurants and other public places. However, the new habit of sitting is estimated to cause greater losses in the coming years.
Lack of Movement Gives Rise to a Range of Dangerous Diseases
Changing lifestyles that are best described by negligible walking are likely to cause a new range of preventable diseases amongst Americans. The biggest challenge created by doing nothing but sitting – as the commute is through vehicles, working is at desks, east and drinking is at tables, and then sleeping in bed – is obesity. The National Institutes of Health stated that obesity and being overweight leads to 300,000 deaths every year. The Centers for Disease Control and Prevention reported that though the deaths due to lung cancer have dropped by 2%, while the issue of obesity seems to be on the rise. By the end of 2015, about 20% of the adults were suffering from obesity.
In the wake of the aforementioned lifestyle changes, sedentary lifestyles, and subsequent obesity, the world is likely to see a rise in the cases of cardiovascular diseases, diabetes, and cancer among others. Prolonged sitting is also expected to cause venous insufficiency, which causes blood to pool in legs. A lot of body’s functioning relies on the movement it receives. Thus, it is extremely important for people to keep walking or to incorporate exercise in daily routine in order to achieve healthier bodies that will function better over a long period of time.